Successful treatment with nivolumab in a patient with unresectable oral squamous cell carcinoma following ineffective chemoradiotherapy

KEY CLINICAL MESSAGE: Nivolumab has been clinically successful in prolonging the overall survival of patients with recurrent and metastatic head and neck cancer, complete remission is rare. Synergistic combinations of immunotherapy and conventional cancer treatments, such as radiotherapy or chemothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Sekido, Katsuhisa, Imaue, Shuichi, Tachinami, Hidetake, Tomihara, Kei, Naruto, Norihito, Yamagishi, Kentaro, Ikeda, Atsushi, Fujiwara, Kumiko, Noguchi, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683031/
https://www.ncbi.nlm.nih.gov/pubmed/38033699
http://dx.doi.org/10.1002/ccr3.8219
Descripción
Sumario:KEY CLINICAL MESSAGE: Nivolumab has been clinically successful in prolonging the overall survival of patients with recurrent and metastatic head and neck cancer, complete remission is rare. Synergistic combinations of immunotherapy and conventional cancer treatments, such as radiotherapy or chemotherapy, are likely to be the most viable strategies for improving patient responses. ABSTRACT: Immune checkpoint inhibitors have revolutionized recurrent, metastatic oral cancer treatment; however complete remission in advanced stages is unusual. We present a case of complete remission of advanced oral squamous cell carcinoma for >4 years in a 64‐year‐old Japanese woman, that responded poorly to chemoradiotherapy but well to subsequent nivolumab treatment.

Ejemplares similares